General
Preferred name
SALMETEROL
Synonyms
SALMETEROL XINAFOATE ()
CHEMBL1263 ()
GR 33343X xinafoate ()
Salmetedur ()
Arial ()
GR33343X ()
Advair-salmeterol xinafoate ()
Salmeterol (xinafoate) ()
GR 33343X xinafoate,Salmetedur ()
Astmerole, GR-33343X, SN408D ()
LIPO-202 ()
GR 33343 G ()
GR-33343X ()
GR-33343 G ()
SEREVENT ()
Salmeterol 1-hydroxy-2-naphthoate ()
SALMATEROL ()
GR-33343-X ()
GR 33343 X ()
SOLTEL ()
NEOVENT ()
VERTINE ()
SN408D ()
BEGLAN ()
NSC-272693 ()
Cryogenine ()
Salmeterol-d3 ()
Salmeterol-d3 (xinafoate) ()
P&D ID
PD002869
CAS
94749-08-3
89365-50-4
497063-94-2
Tags
available
biased GPCR ligand
probe
drug
Approved by
FDA
EMA
First approval
1994
Drug indication
Bronchodilator
Chronic obstructive pulmonary disease
Drug Status
approved
Max Phase
4.0
Probe info
Probe type
calculated probe
Probe sources
Tool Compound Set
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
4
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Salmeterol is a long acting beta2-adrenoceptor agonist (LABA), usually only prescribed for severe persistent asthma following previous treatment with a short-acting beta agonist such as salbutamol and is prescribed concurrently with a corticosteroid, such as beclometasone. The primary noticable difference of salmeterol to salbutamol is that the duration of action lasts approximately 12 hours in comparison with 4-6 hours of salbutamol. It is a maintenance bronchodilator which decreases the number and severity of asthma attacks. However, it is not for use for relieving an asthma attack that has already started.
MOA
Salmeterol's long, lipophilic side chain binds to exosites near beta(2)-receptors in the lungs and on bronchiolar smooth muscle, allowing the active portion of the molecule to remain at the receptor site, continually binding and releasing. Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow. Salmeterol is less potent with a slower onset of action than formoterol, an alternative Beta(2) agonist.
DESCPRITION
Salmeterol is a selective long acting beta2-adrenoceptor agonist. In vitro studies show salmeterol to be at least 50 times more selective for beta2-adrenoceptors than albuterol. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from human lung. Salmeterol inhibits histamine-induced plasma protein extravasation and inhibits platelet-activating factor-induced eosinophil accumulation in the lungs of guinea pigs when administered by the inhaled route. In humans, single doses of salmeterol administered via inhalation aerosol attenuate allergen-induced bronchial hyper-responsiveness.
DESCRIPTION
Selective A2B antagonist
(Tocris Bioactive Compound Library)
DESCRIPTION
Long-acting beta2 agonist; bronchodilator
(Tocriscreen Plus)
DESCRIPTION
beta2 Adrenoceptor agonist
(LOPAC library)
DESCRIPTION
Potent β2 agonist; long acting
(Tocriscreen Total)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
3
Compound Sets
36
BiasDB
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
Ki Database
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
Tool Compound Set
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
79
Molecular Weight
415.27
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
4
Rotatable Bonds
16
Ring Count
2
Aromatic Ring Count
2
cLogP
4.11
TPSA
81.95
Fraction CSP3
0.52
Chiral centers
1.0
Largest ring
6.0
QED
0.31
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Beta-2 adrenergic receptor
??2-adrenergic receptor
WT ??2AR
??2-adrenoceptor
¦Â2-adrenergic receptor
Adrenergic Receptor
Target Type
7-TM Receptors
Selectivity
beta2
Pathway
GPCR/G protein
Microbiology&virology
Proteases/Proteasome
Neuroscience
Neuronal Signaling
Primary Target
Adrenergic ?2 Receptors
MOA
Adrenergic Receptor agonist
Agonist
Biosynthetic Origin
Alkaloid
Therapeutic Indication
Bronchodilator
Therapeutic Class
Respiratory
Bronchodilator Agents
Recommended Cell Concentration
None
Source data
